Bibhitaki: Traditional Uses, Dosage, Evidence & Safety

TL;DR

Bibhitaki (Terminalia bellirica) is a classical Ayurvedic fruit drug and one-third of Triphala, used traditionally for cough, constipation, and eye health. I read the human trials end to end. I found two, both small: a 24-week pilot RCT on uric acid and a crossover study on bowel habits. Traditional powder dose is 3–6 g. Too thin to recommend any dose.

What it is

Bibhitaki is the dried fruit of Terminalia bellirica Roxb., family Combretaceae. Small nomenclature wrinkle: the Ayurvedic Pharmacopoeia of India spells the species Terminalia belerica. The API (Part I, Volume I) defines the official drug as the pericarp of the dried ripe fruit (monograph). It is the second of Triphala's three fruits: equal parts amalaki, bibhitaki, and haritaki (Triphala composition review). Among its constituents, the API lists gallic acid, tannic acid, and glycosides (monograph).

Traditional use

The API describes bibhitaki as astringent in taste, light and dry in quality, hot in potency, with a sweet post-digestive effect. Its listed actions: benefit to the eyes (caksusya) and hair (kesya), pacification of kapha and pitta, purgative action (bhedaka), anthelmintic action, and relief of cough (monograph). Classical indications run to vomiting, cough, worm infestation, constipation, hoarseness, and eye disorders, and the fruit appears in formulations including Triphala Churna, Triphaladi Taila, and Lavangadi Vati (monograph). All of this is traditional and pharmacopoeial claim, not clinical proof. The human evidence gets its own hearing below.

What modern research says

Uric acid (hyperuricemia)

This is the strongest human evidence bibhitaki has, and it is still a pilot. In a 24-week, randomized, double-blind, placebo- and positive-controlled trial, 110 adults with asymptomatic hyperuricemia were enrolled (88 completed) across five arms: bibhitaki 250 mg twice daily, bibhitaki 500 mg twice daily, haritaki 500 mg twice daily, febuxostat 40 mg, and placebo; CTRI Ref/2014/09/007548. The test article was a standardized aqueous fruit extract (Ayuric®, Natreon). At 500 mg twice daily, mean serum uric acid fell from 8.07±0.87 to 5.78±0.25 mg/dL, roughly twice the reduction seen with haritaki 500 mg, though less than febuxostat (8.53±0.97 to 4.28±0.67 mg/dL). The 250 mg dose did less, which suggests the effect is dose-dependent (Usharani et al., 2016).

Now the caveats, because they matter. The trial enrolled only asymptomatic hyperuricemia; people with gout flares were excluded. It was small and explicitly a pilot. All formulations were well tolerated. The authors called for confirmatory studies (Usharani et al., 2016). And the results apply to the proprietary standardized extract. Not to traditional powder, not to whatever is on a store shelf.

Bowel habits and gut microbiome

A Japanese randomized, double-blind, placebo-controlled crossover study took 46 healthy adults with a tendency toward constipation and gave them a T. bellirica fruit extract supplying 20.8 mg of gallic acid per day, for four weeks (abstract record). The trial record reports increased defecation frequency, defecation days, and stool amount, plus changes in gut microbiome alpha diversity, and no adverse events attributable to the extract. It was registered as UMIN000053709 (abstract record). Small. Short. Available only as an abstract record; I could not identify the full journal publication. Treat it as preliminary.

Lab-only findings (not human evidence)

In mice, a T. bellirica extract was studied in a colitis model (MDPI Molecules). In cell culture, extracts inhibited LDL oxidation and macrophage inflammatory responses (MDPI Antioxidants). Preclinical. Interesting. Not human evidence, and it establishes no human benefit.

What the evidence does not support (yet)

Beyond those two small human studies, most of what is claimed for bibhitaki (the classical eye, hair, cough, and digestive indications included) has no clinical trials behind it. One more boundary worth drawing: Triphala-formula trials do not count as evidence for bibhitaki alone.

Dosage

The API's dose for bibhitaki fruit powder is 3–6 g (monograph). The trials used proprietary extracts, not powder: Ayuric® (standardized aqueous extract) at 250 mg or 500 mg twice daily for 24 weeks (Usharani et al., 2016), and a fruit extract supplying 20.8 mg gallic acid daily for four weeks in the constipation-tendency study (abstract record). Do not equate retail products with trial extracts. The evidence is too thin to recommend any dose. This section reports what was used, nothing more.

Safety & contraindications

The 24-week pilot monitored hematological, hepatic, and renal parameters and reported the formulations well tolerated, with no serious adverse effects (Usharani et al., 2016). The Japanese study reported no adverse events attributable to the extract (abstract record). Dedicated long-term safety studies were not identified. A recent review urges careful use. It notes blood-sugar-lowering effects and advises against use in pregnancy (JAIMS review). Worth knowing: the hyperuricemia trial excluded pregnant and lactating women, and people with uncontrolled hypertension or diabetes, or renal or hepatic impairment (Usharani et al., 2016). Discuss use with a clinician if you are pregnant, breastfeeding, managing diabetes or any condition, or taking prescription medicines.

FAQs

What is bibhitaki?

Bibhitaki is the dried fruit (pericarp) of Terminalia bellirica, a classical Ayurvedic fruit drug and one-third of the formula Triphala: equal parts amalaki, bibhitaki, and haritaki (monograph; Triphala composition review).

Is bibhitaki the same as Triphala?

No. Bibhitaki is one of Triphala's three fruits, alongside haritaki and amalaki. Trials of Triphala as a formula do not prove bibhitaki's individual effects (Triphala composition review).

What is bibhitaki used for traditionally?

Classically it is listed for vomiting, cough, worm infestation, constipation, hoarseness, and eye disorders, with actions described as purgative, anthelmintic, cough-relieving, and beneficial to eyes and hair (monograph). These are traditional claims, not clinical evidence.

Does bibhitaki lower uric acid or treat gout?

One small 24-week pilot RCT found a standardized extract at 500 mg twice daily lowered mean serum uric acid in adults with asymptomatic hyperuricemia. It was not a gout trial (participants with gout flares were excluded), and the authors called for confirmatory studies (Usharani et al., 2016).

How much bibhitaki powder is used?

The API's classical dose for fruit powder is 3–6 g (monograph). Clinical studies used proprietary extracts at different doses, which are not equivalent to powder. The evidence is too thin to recommend any dose.

Is bibhitaki safe in pregnancy?

Pregnancy has not been studied; a recent review advises against use during pregnancy and notes possible blood-sugar-lowering effects (JAIMS review). Avoid use in pregnancy and discuss with a clinician if breastfeeding or managing diabetes.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.